Partial approval for Amgen bone drug
Posted on: Friday, 14 August 2009, 11:07 CDT
Amgen's bone drug, denosumab, has been partially endorsed by an advisory committee to the U.S. Food and Drug Administration, officials said.
In a unanimous vote Thursday, the committee said denosumab should be approved to treat post menopausal women with osteoporosis, The New York Times reported Friday.
However, the committee voted 12 to 3 against denosumab being used to prevent osteoporosis in women with moderately low bone density, and it opposed three of four possible uses for prostate and breast cancer patients whose therapy can weaken bones.
The committee said it was concerned about a slight increase in some infections and cancers in patients receiving denosumab when compared with those taking placebos in clinical trials.
The FDA tentatively is to decide in October whether to approve the drug, which would be marketed under the name Prolia.
In clinical trials involving 8,000 women, 2.3 percent of those taking denosumab had a vertebral fracture over three years, compared with 7.2 percent of women taking placebos.
Source: United Press International
Related Articles
- Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer
- On Valentine's Day, Abbott Urges Women to Take Heart With Launch of 'Faces of Heart Disease' Exhibit to Raise Heart Health Awareness
- Popular Author, Speaker, and Pastor Seeks 8,000 Women To Take The Pledge To Better Health
- Drop-in Center for Women Drug Users in Nepali Capital
- Women filmmakers take new direction at Sundance
- Slimming Drug Takes Weight and Memory
- Life in Open Prisons 'Leads to Drug Taking'
- Wal-Mart and Speaking of Women's Health Encourage Women to Take a Pledge for Better Health
- Cox-2 Drugs Take Center Stage at Gov't Hearings
- Senate Committee Gives Drug Plan Quick OK
 |
 |
User Comments (0)
RSS Feeds